Tips on using ruxolitinib in everyday practice as therapy for myelofibrosis

Leukemia and Lymphoma

Volumn 55, Issue 1, 2014, Pages 5-6

  Verstovsek, Srdan ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DANAZOL; ERYTHROPOIETIN; HEMOGLOBIN; RUXOLITINIB; THALIDOMIDE;

ANEMIA; BONE MARROW SUPPRESSION; CLINICAL STUDY; HEMOGLOBIN BLOOD LEVEL; HEPATOMEGALY; HUMAN; MYELOFIBROSIS; NOTE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; SPLENECTOMY; SPLENOMEGALY; SURVIVAL TIME; WITHDRAWAL SYNDROME;

ANTINEOPLASTIC AGENTS; HUMANS; PRIMARY MYELOFIBROSIS; PYRAZOLES;

EID: 84891367606     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.802318     Document Type: Note

References (10)

1. Mascarenhas J, Mughal TI, Verstovsek S. Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib. Curr Med Chem 2012; 19: 4399-4413.
2. Verstovsek S. Ruxolitinib: An oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofi brosis. Postgrad Med 2013; 125: 128-135.
3. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, aJAK1 and JAK2 inhibitor, in myelofi brosis. N Engl J. Med 2010; 363: 1117-1127.
4. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebocontrolled trial of ruxolitinib for myelofi brosis. N Engl J. Med 2012; 366: 799-807.
5. Benjamini O, Jain P, Estrov Z, et al. Therapeutic effects of ruxolitinib in patients with myelofi brosis without clinically significant splenomegaly. Blood 2012; 120: 2768-2769.
6. Verstovsek S, Kantarjian HM, Estrov Z, et al. Long-Term outcomes of 107 patients with myelofi brosis receiving JAK1/JAK2 inhibitor ruxolitinib: Survival advantage in comparison to matched historical controls. Blood 2012; 120: 1202-1209.
7. Verstovsek S, Mesa RA, Gotlib J, et al. Long-Term outcome of ruxolitinib treatment in patients with myelofi brosis: Durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT-I. Blood 2012; 120(Suppl. 1): Abstract 800.
8. Geyer H, Cannon K, Knight E, et al. Ruxolitinib in clinical practice for therapy of myelofi brosis: Single USA center experience following Food and Drug Administration approval. Leuk Lymphoma 2014; 55: 195-197.
9. Talpaz M, Paquette R, Afrin L, et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofi brosis patients with low starting platelet counts (50-100 x 109/L): A comparison to patients with normal or high starting platelet counts. Blood 2012; 120(Suppl. 1): Abstract 176.
10. Mascarenhas J, Hoffman R. A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofi brosis. Blood 2013; 121: 4832-4837.